Compare 10X Genomics Inc (TXG) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
10X Genomics Inc vs Yum! Brands, Inc. — how do they compare? 10X Genomics Inc trades at $57.71 (market cap $7.61B), while Yum! Brands, Inc. trades at $148.84 (market cap $39.50B). The key difference: Yum! Brands, Inc. is far larger — about 5.2× 10X Genomics Inc's market cap, and Yum! Brands, Inc. pays a 2.07% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| TXG | YUM | |
|---|---|---|
Market Cap | $7.61B | $39.50B |
Sector | Health | Consumer Cyclical |
52-Week High | $58.57 | $168.16 |
52-Week Low | $11.34 | $138.21 |
Enterprise Value | $7.14B | $51.10B |
Dividend Yield | — | 2.07% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TXG trades at $58.57, up 12.57% in 24 hours, reflecting strong momentum. The stock is technically bullish with moving averages supporting the uptrend, though RSI levels suggest overbought conditions. Fundamentally, the company shows improving trends with Q2 2026 earnings beating estimates and revenue growth, yet remains unprofitable with a negative net income margin. Recent news highlights collaborations and acquisitions expanding its genomic capabilities.
Outlook is mixed; analyst consensus is neutral with a $46 price target below current levels, indicating caution despite recent beats. Key risks include sustained losses and competitive pressures, but operational cash flow growth and strategic expansions offer potential upside for patient investors focused on long-term biotech innovation.
YUM trades at $145.33, down 3.6% amid bearish technical signals and recent parasite outbreak concerns affecting Taco Bell sales. The company reported strong Q2 2026 earnings of $1.62 per share, beating estimates, with revenue growth continuing from $8.21B in 2025 to projected $8.7B in 2026. Valuation metrics show a P/E of 18.23 and P/S of 4.63, while debt reduction improved with debt-to-asset ratio declining to 143.49 in 2025.
The outlook remains mixed with analyst consensus price target of $174.60 suggesting 20% upside, but legal investigations and food safety issues pose near-term risks. Long-term growth drivers include digital expansion and portfolio optimization following Pizza Hut China sale, though execution on Taco Bell recovery is critical for sentiment improvement.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
